ROCKVILLE, Md., Feb. 2 /PRNewswire/ -- Accelovance announced today that it
has completed the asset purchase of nTouch Research, a Raleigh, N.C.-based
site management organization (SMO). Financial details were not disclosed.
nTouch's clinical capabilities are a key component in Accelovance's strategy
to provide trial management services that result in meeting trial timelines in
a high quality and cost-effective manner. By combining high-level targeted
patient recruitment with quality-focused, integrated, and centralized managed
sites, Accelovance improves productivity and quality when conducting multi-
center Phase II through IV studies. Building on its operations in China, the
Company plans to add clinical sites there to further enhance global clinical
trial enrollment and economics.
"A strategic blend of upper management expertise, outstanding
investigators, and the knowledge of on-site employees will allow Accelovance
to better serve our clients. Our vision is to revitalize the way SMOs and
trial sponsors work together," said Accelovance President and CEO, Stephen J.
Accelovance is a privately held company headquartered in Rockville,
Maryland. With over a dozen highly-rated research centers throughout the
United States, Accelovance provides Phase II-IV clinical trial services that
include investigator selection, patient recruitment and study management
services for pharmaceutical, CRO, and biotechnology industries. Accelovance
has a commitment to sponsors, investigators and study subjects to conduct each
study with dedication and high standards under good clinical practice (GCP)
guidelines. Its secondary mission is to form strong partnerships to take
advantage of the rapidly growing medical market in China. This will be
accomplished by structuring relationships between partners with quality
products and services to address unmet medical needs in China.
For more information, visit the company's website at
CONTACT: Stephen J. Trevisan, +1-301-222-2218, or Garrett D. Smith,
+1-301-222-2212, both of Accelovance.